Table 2.
Impact indicators for DiBP in children (HBM4EU Aligned Study data).
| Study name, Country | N | P95 [μg/L] | Number of participants exceeding the HBM-GVchildren | Percentage of participants exceeding the HBM-GVchildren [%] | Extent of exceedance [P95/HBM-GVchildren] |
|---|---|---|---|---|---|
| OCC, Denmark | 300 | 56.9 | 0 | 0 | 0.36 |
| NEB II, Norway | 300 | 140.6 | 13 | 4.3 | 0.88 |
| InAirQ, Hungary | 262 | 148.0 | 11 | 4.2 | 0.92 |
| PCB cohort, Slovakia | 296 | 245.7 | 36 | 12.2 | 1.54 |
| CROME, Greece | 161 | 160.6 | 9 | 5.6 | 1.00 |
| NAC II, Italy | 299 | 96.4 | 5 | 1.7 | 0.60 |
| SLO CRP, Slovenia | 149 | 129.8 | 4 | 2.7 | 0.81 |
| 3xG, Belgium | 133 | 123.5 | 3 | 2.3 | 0.77 |
| ESTEBAN, France | 286 | 180.3 | 17 | 5.9 | 1.13 |
| GerES V, Germany | 300 | 111.1 | 8 | 2.7 | 0.69 |
| SPECIMEn-NL, The Netherlands | 89 | 56.6 | 1 | 1.1 | 0.35 |
N = number of participants.